Results 251 to 260 of about 8,474,282 (288)

Impact of donor-specific antibodies on results of liver transplantation

Current Opinion in Organ Transplantation, 2013
To critically examine the recent literature evaluating the importance of HLA donor-specific antibody (DSA) impact on liver transplant and simultaneous liver-kidney transplant (SLKT) outcomes.Many preformed DSAs, especially of low mean fluorescence intensity (MFI), are absorbed by the liver at transplant. However, patients with post-liver transplant DSA,
Jacqueline G, O'Leary, Göran B, Klintmalm   +1 more
openaire   +2 more sources

Donor-specific antibodies in allograft recipients

Current Opinion in Organ Transplantation, 2014
Kidney transplantation remains the treatment of choice for patients with end-stage renal failure. However, despite significant advancements in detection of donor-specific human leukocyte antigen antibodies, improved immunosuppression and patient management, the durability of this life-saving therapy has not improved. This results in increased morbidity
Stanley C, Jordan, Ashley A, Vo
openaire   +2 more sources

The clinical impact of donor-specific antibodies in heart transplantation

Transplantation Reviews, 2018
Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection (AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac allograft vasculopathy (CAV). Anti-donor HLA antibodies are present in 3-11% of patients at the time of heart transplantation (HTx), with de novo DSA (predominantly anti ...
Markus J. Barten, Uwe Schulz, Andres Beiras-Fernandez, Michael Berchtold-Herz, Udo Boeken, Jens Garbade, Stephan Hirt, Manfred Richter, Arjang Ruhpawar, Tim Sandhaus, Jan Dieter Schmitto, Felix Schönrath, Rene Schramm, Martin Schweiger, Markus Wilhelm, Andreas Zuckermann   +15 more
openaire   +5 more sources

Using Donor-Specific Antibodies to Monitor the Need for Immunosuppression

Transplantation, 2012
Experience with tolerance protocols has shown that none is perfect and that each escape from tolerance must be identified early to prevent graft failure. In addition, some test is needed for patients who are weaned off immunosuppression (IS) to forewarn of weaning failure.
Junichi, Hoshino, Hugo, Kaneku, Matthew J, Everly, Sander, Greenland, Paul I, Terasaki   +4 more
openaire   +2 more sources

The meaning of donor-specific antibodies after heart transplant

Current Opinion in Organ Transplantation, 2019
Purpose of review Antibody-mediated rejection (AMR) is a major contributor of impaired long-term survival after heart transplantation (HTx). The presence of circulating donor-specific antihuman leukocyte antigen (HLA) antibodies (DSAs) is considered as a mandatory criterion for AMR after HTx. DSA are known prognostic biomarkers
Markus J, Barten, Andreas, Zuckermann
openaire   +2 more sources

Donor-Specific Antibodies: Clinical Relevance of Antibodies Detected in Lymphocyte Crossmatches

Clinics in Laboratory Medicine, 1991
Positive donor crossmatches due to lymphocytotoxic antibodies generally have an adverse effect on allograft survival, but with numerous variations. Different laboratory techniques used to characterize lymphocytotoxic antibody, new antibody systems, such as those incited by endothelial/monocyte and epithelial antigens, the variable tempos and ...
openaire   +2 more sources

Proteasome Inhibition Reduces Donor-Specific Antibody Levels

Transplantation Proceedings, 2009
Current antibody-mediated rejection (AMR) therapies (intravenous immunoglobulin, apheresis, rituximab, polyclonal antibodies) do not target the primary antibody producing B cells, that is, the plasma cell. We report the preliminary results from the first clinical experience with plasma cell targeted therapy with bortezomib.
M J, Everly, J J, Everly, B, Susskind, P, Brailey, L J, Arend, R R, Alloway, P, Roy-Chaudhury, A, Govil, G, Mogilishetty, A H, Rike, M, Cardi, G, Wadih, E, Brown, A, Tevar, E S, Woodle   +14 more
openaire   +2 more sources

Mechanisms of Antibody Mediated Rejection in the Absence of Donor Specific Antibodies

The Journal of Heart and Lung Transplantation, 2019
Purpose Antibody mediated rejection (AMR) is an increasingly studied cause of graft failure and cardiac allograft vasculopathy. The 1990 ISHLT Working Formulation first defined AMR as positive immunofluorescence staining of active complement in the graft endothelium and/or histologic evidence of vasculitis or severe edema in the absence of cellular ...
S.B. See, B.S. Mantell, K.J. Clerkin, B. Ray, R.E. Vasilescu, C.C. Marboe, Y. Naka, S. Restaino, P.C. Colombo, L.J. Addonizio, M.A. Farr, E. Zorn   +11 more
openaire   +1 more source

Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection

Clinics in Laboratory Medicine, 2019
This article reviews the current evidence to classify donor-specific antibodies (DSAs) using Food and Drug Administration-National Institutes of Health Biomarkers, EndpointS, and other Tools (BEST) resource terms as diagnostic, prognostic, predictive, monitoring, and risk biomarkers for graft rejection. The emphasis is on DSA characteristics, including
openaire   +2 more sources

Donor-Specific Antibody Monitoring: Where Is the Beef?

Advances in Chronic Kidney Disease, 2016
This review paper discusses the impact of de novo donor-specific antibodies (DSA) to donor HLA antigens in kidney transplantation and summarizes the benefits and challenges that exist with DSA monitoring. Post-transplant DSA is associated with worse allograft outcomes and its detection may precede or coincide with clinical, biochemical, and histologic ...
Jeffrey, Ma, Anita, Patel, Kathryn, Tinckam   +2 more
openaire   +2 more sources